Duragesic® (Fentanyl Transdermal System) Functionality Trial in Chronic Low Back Pain
CompletedPhase 4NCT00237341
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to assess physical functionality changes over a minimum of 9 weeks in patients with non-malignant chronic low back pain who are taking short-acting opioids (narcotic pain medications) for 4 or more weeks, and who start taking the long-acting opioid fentanyl in the form of a transdermal (skin) patch.
Study details
- Official title
- Assessing Functionality Changes Associated With Patients Who Were Taking Short Acting Opioids Chronically and Who Initiated Treatment With Duragesic® (Fentanyl Transdermal System) for the Management of Chronic Low Back Pain.
- Conditions
- Interventions
- Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
- Start date
- 2002-06
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Chronic low back pain (not related to cancer) for at least 3 months * current use of short-acting opioid (narcotic pain medication) for at least 4 weeks * initiating fentanyl transdermal patch. Exclusion Criteria: * Confusion or reduced level of consciousness * skin disease * malignancies (cancer) * currently hospitalized * treated with a long-acting opioid within the last 2 months * pregnant or breast-feeding * abusing drugs or alcohol
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00237341